Xia and colleagues, who reported that high levels of IgM+ memory B cells prior to therapy with anti-PD-1 associated with NSCLC response, also showed that percentages of PD-1+ IgM+ memory B cells were reduced in responding patients, while percentages of PD-L1+ IgM+ memory B cells were increased in responding patients [77]. This evidence concerns the gene CD274 and non-small cell lung carcinoma.